Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors

Pediatric Infectious Disease Journal

Volumn 25, Issue 2, 2006, Pages 135-141

  Alexander, Louis ^a   Cuchura, Lisa ^a   Simpson, B Joyce ^b   Andiman, Warren A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN CHILDREN S HOSPITAL   (United States)

Author keywords

Human immunodeficiency virus type 1; Long term survival; Pediatric

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR2; GAG PROTEIN; HLA DQ1 ANTIGEN; HLA DQ2 ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIF PROTEIN; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DNA POLYMORPHISM; GENE INSERTION; GENOTYPE; HETEROZYGOSITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 32144459805     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000199299.00345.83     Document Type: Article

References (47)

1. Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med. 1989;321:1791-1796.
2. Simpson BJ, Shapiro ED, Andiman WA. Prospective cohort study of children bom to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy. Pediatr Infect Dis J. 2000;19:618-624.
3. Alexander L, Weiskopf E, Greenough TC, et al. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol. 2000;74:4361-4376.
4. Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med. 1999;340:1715-1722.
5. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995;332:209-216.
6. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273:1856-1862.
7. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature. 1996;384:529-534.
8. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240-1243.
9. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 1998;4:350-353.
10. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
11. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
12. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-393.
13. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis. 1997;176:118-125.
14. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 1996;156:2616-2623.
15. Rodes B, Toro C, Paxinos E, et al. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS. 2004;18:1109-1116.
16. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283:1748-1752.
17. Geczy AF, Kuipers H, Coolen M, et al. HLA and other host factors in transfusion-acquired HIV-1 infection. Hum Immunol. 2000;61:172-176.
18. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA. 2000;97:2709-2714.
19. Alexander L, Aquino-DeJesus MJ, Chan M, Andiman WA. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol. 2002;76:10533-10539.
20. Binley JM, Jin X, Huang Y, et al. Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression. J Virol. 1998;72:3472-4.
21. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995;270:988-91.
22. Iversen AK, Shpaer EG, Rodrigo AG, et al. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol. 1995;69:5743-5753.
23. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995;332:228-232.
24. Wang B, Ge YC, Palasanthiran P, et al. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology. 1996;223:224-232.
25. Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocytes responses in the first year of life. J Immunol. 1995;154:433-443.
26. Luzuriaga K, McQuilken P, Almenti A, Somasundaran M, Hesselton R, Sullivan JL. Early Viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis. 1993;167:1008-1013.
27. Pugatch D, Sullivan JL, Pikora CA, Luzuriaga K. Delayed generation of antibodies mediating human immunodeficiency virus type 1-specific antibody-dependent cellular cytotoxicity in vertically infected infants. WITS Study Group. Women and Infants Transmission Study. J Infect Dis. 1997;176:643-648.
28. + T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
29. Feeney ME, Roosevelt KA, Tang Y, et al. Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. J Virol. 2003;77:7492-7501.
30. Fang G, Burger H, Grimson R, et al. Maternal plasma puman immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child cransmission. Proc Natl Acad Sci U S A. 1995;92:12100-12104.
31. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
32. Kestler HW, 3rd, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991;65:651-662.
33. Lang SM, Weeger M, Stahl-Hennig C, et al. Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol. 1993;67:902-912.
34. Alexander L, Du Z, Howe AY, Czajak S, Desrosiers RC. Induction of AIDS in rhesus monkeys by a recombinant simian immunodeficiency virus expressing nef of human immunodeficiency virus type 1. J Virol. 1999;73:5814-5825.
35. Whatmore AM, Cook N, Hall GA, Sharpe S, Rud EW, Cranage MP. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol. 1995;69:5117-5123.
36. Paul ME, Mao C, Charurat M, et al. Predictors of immunologic long-term nonprogression in HIV-infected children: implications for initiating therapy. J Allergy Clin Immunol. 2005;115:848-855.
37. Aquino-De Jesus MJ, Anders C, Miller G, Sleasman JW, Goodenow MM, Andiman WA. Genetically and epidemiologically related "non-syncytium- inducing" isolates of HIV-1 display heterogeneous growth patterns in macrophages. J Med Virol. 2000;61:171-180.
38. HIV Sequence Compendium 2000. Theoretic Biology and Biophysics Group, Los Alamos laboratory, Los Alamos, New Mexico, 2001.
39. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986;59:284-291.
40. Naidu YM, Kestler HW, 3rd, Li Y, et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol. 1988;2:4691-4696.
41. Vartdal F, Bratlie A, Gaudernack G, Funderud S, Lea T, Thorsby E. Microcytotoxic HLA typing of cells directly isolated from blood by means of antibody-coated microspheres. Transplant Proc. 1987;19:655-657.
42. Vartdal F, Gaudernack G, Funderud S, et al. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation - a fast and reliable technique. Tissue Antigens. 1986;28:301-312.
43. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA. 1998;279:1984-1991.
44. Lum JJ, Cohen OJ, Nie Z, et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest. 2003;111:1547-1554.
45. Freed EO, Martin MA. HIVs and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1971-2042.
46. de Vries RP, Kreeftenberg HJ, Loggen HG, van Rood JJ. In vitro immune responsiveness to vaccinia virus and HLA. N Engl J Med. 1977;297:692-696.
47. Boucher K, Mori M, Milford E, Beatty PG. Estimation of HLA-A, -B, -DR haplotype frequencies in five racial groups represented in the NMDP Donor File. In: Gjertson DW, Teraski PI, eds. HLA. 1998:57-78.